REYON Pharmaceutical Co., Ltd.

KOSE:A102460 Stok Raporu

Piyasa değeri: ₩303.7b

REYON Pharmaceutical Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

REYON Pharmaceutical has been growing earnings at an average annual rate of 13.7%, while the Pharmaceuticals industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 4.3% per year.

Anahtar bilgiler

13.7%

Kazanç büyüme oranı

12.5%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi11.3%
Gelir büyüme oranı4.3%
Özkaynak getirisi-0.04%
Net Marj-0.07%
Son Kazanç Güncellemesi30 Jun 2024

Yakın geçmiş performans güncellemeleri

There May Be Reason For Hope In REYON Pharmaceutical's (KRX:102460) Disappointing Earnings

Mar 31
There May Be Reason For Hope In REYON Pharmaceutical's (KRX:102460) Disappointing Earnings

Recent updates

REYON Pharmaceutical Co., Ltd.'s (KRX:102460) Shareholders Might Be Looking For Exit

Oct 18
REYON Pharmaceutical Co., Ltd.'s (KRX:102460) Shareholders Might Be Looking For Exit

There May Be Reason For Hope In REYON Pharmaceutical's (KRX:102460) Disappointing Earnings

Mar 31
There May Be Reason For Hope In REYON Pharmaceutical's (KRX:102460) Disappointing Earnings

Consider This Before Buying REYON Pharmaceutical Co., Ltd. (KRX:102460) For The 1.6% Dividend

May 08
Consider This Before Buying REYON Pharmaceutical Co., Ltd. (KRX:102460) For The 1.6% Dividend

Here's Why REYON Pharmaceutical (KRX:102460) Has A Meaningful Debt Burden

Apr 09
Here's Why REYON Pharmaceutical (KRX:102460) Has A Meaningful Debt Burden

What Percentage Of REYON Pharmaceutical Co., Ltd. (KRX:102460) Shares Do Insiders Own?

Feb 28
What Percentage Of REYON Pharmaceutical Co., Ltd. (KRX:102460) Shares Do Insiders Own?

Read This Before Buying REYON Pharmaceutical Co., Ltd. (KRX:102460) For Its Dividend

Jan 20
Read This Before Buying REYON Pharmaceutical Co., Ltd. (KRX:102460) For Its Dividend

REYON Pharmaceutical (KRX:102460) Seems To Use Debt Quite Sensibly

Jan 02
REYON Pharmaceutical (KRX:102460) Seems To Use Debt Quite Sensibly

Did REYON Pharmaceutical's (KRX:102460) Share Price Deserve to Gain 50%?

Dec 12
Did REYON Pharmaceutical's (KRX:102460) Share Price Deserve to Gain 50%?

How Much Of REYON Pharmaceutical Co., Ltd. (KRX:102460) Do Insiders Own?

Nov 24
How Much Of REYON Pharmaceutical Co., Ltd. (KRX:102460) Do Insiders Own?

Gelir ve Gider Dağılımı

REYON Pharmaceutical nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

KOSE:A102460 Gelir, gider ve kazançlar (KRW Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Jun 24148,991-10463,9953,951
31 Mar 24151,0561,90264,6036,935
31 Dec 23151,0713,58364,2438,375
30 Sep 23150,5848,45664,48910,363
30 Jun 23152,04310,61464,3269,826
31 Mar 23153,9077,50365,7328,274
31 Dec 22154,0397,35966,2066,705
30 Sep 22152,5494,81666,9365,410
30 Jun 22150,2372,77466,4427,878
31 Mar 22146,3296,26564,2159,161
31 Dec 21142,8015,41263,6199,725
30 Sep 21139,4145,65062,11410,372
30 Jun 21135,8936,51862,0257,890
31 Mar 21131,3034,84359,6416,508
31 Dec 20130,0343,84459,7656,584
30 Sep 20129,7381,72061,2765,255
30 Jun 20129,6842,16561,6854,370
31 Mar 20131,5812,16562,8203,587
31 Dec 19131,5584,94659,8763,724
30 Sep 19128,2671,47860,7544,580
30 Jun 19125,96359460,3354,580
31 Mar 19124,1923,29960,5845,045
31 Dec 18122,9901,34357,4246,697
30 Sep 18122,8507,02153,0815,857
30 Jun 18123,9369,64352,2135,857
31 Mar 18124,1509,07348,5106,132
31 Dec 17126,25312,88751,3403,454
30 Sep 17126,74813,19551,2974,522
31 Dec 16121,84710,70148,4966,495

Kaliteli Kazançlar: A102460 is currently unprofitable.

Büyüyen Kar Marjı: A102460 is currently unprofitable.


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: A102460 is unprofitable, but has reduced losses over the past 5 years at a rate of 13.7% per year.

Büyüme Hızlandırma: Unable to compare A102460's earnings growth over the past year to its 5-year average as it is currently unprofitable

Kazançlar vs. Sektör: A102460 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (21.9%).


Özkaynak Getirisi

Yüksek ROE: A102460 has a negative Return on Equity (-0.042%), as it is currently unprofitable.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin